As­traZeneca's suc­ces­sor to Covid block­buster Evusheld suc­ceeds in Phase 3 tri­al

As­traZeneca’s lat­est an­ti­body to pre­vent Covid-19 hit on both of its pri­ma­ry end­points in a large Phase 3 tri­al, the UK com­pa­ny said Thurs­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.